Oxygenta Pharmaceutical Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
For the six months, sales was INR 199.4 million compared to INR 149.5 million a year ago. Revenue was INR 199.41 million compared to INR 149.5 million a year ago. Net loss was INR 77.19 million compared to INR 40.3 million a year ago. Basic loss per share from continuing operations was INR 2.52 compared to INR 2.84 a year ago. Diluted loss per share from continuing operations was INR 2.41 compared to INR 2.84 a year ago.